# The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations

> **NCT04363840** · PHASE2 · WITHDRAWN · sponsor: **Louisiana State University Health Sciences Center in New Orleans**

## Conditions studied

- COVID
- Vitamin D Deficiency
- Coagulopathy
- Disseminated Intravascular Coagulation

## Interventions

- **DRUG:** Aspirin 81 mg
- **DIETARY_SUPPLEMENT:** Vitamin D

## Key facts

- **NCT ID:** NCT04363840
- **Lead sponsor:** Louisiana State University Health Sciences Center in New Orleans
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of funding
- **Last updated:** 2021-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04363840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04363840, "The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04363840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*